Publication: Biospace
A Massachusetts-based neuro-physiology company developing a new class of digital therapeutics to treat neurodegenerative disorders presented key findings from clinical research at the Alzheimer’s Association International Conference in 2021. These results reported the impact of gamma frequency neuro-modulation on cognitive function in Alzheimer’s Disease, which showed improvements in sleep, improvements in memory and cognition, as well as a reduction in brain atrophy and volumetric loss. The treatment group demonstrated a significant, 65% reduction in Whole Brain Volume loss as compared to the sham group over the same interventional period.
